---
document_datetime: 2024-09-25 09:26:50
document_pages: 23
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/orkambi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: orkambi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 15.0751878
conversion_datetime: 2025-12-18 22:46:22.757196
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Orkambi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0092               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 20/09/2024                          |                                             | Labelling and PL                 |           |
| IB/0090/G            | This was an application for a group of variations.                                               | 24/08/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | stability protocol B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.g.5.b - Implementation of changes foreseen in an approved change management protocol - Requires further supporting data B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary   |            |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0088 | Submission of the final report from study VX19-809- 124 (Study 124), listed as a category 3 study in the RMP. This is a Phase 3, open-label, rollover study to evaluate the long-term safety and tolerability of lumacaftor/ivacaftor in cystic fibrosis subjects homozygous for F508del who were 1 to <2 years of age at treatment initiation and who completed the Safety Follow Up (SFU) visit in Study 122 (Part B) or were lumacaftor/ivacaftor naϊve. The RMP version                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/05/2024 | n/a | This is the final report for study VX19-809-124, an open- label, rollover study evaluating the long-term safety and tolerability of lumacaftor/ivacaftor in cystic fibrosis subjects homozygous for F508del, listed as a category 3 study in the RMP. The long-term safety results in this final report are consistent with the known safety profile of lumacaftor/ivacaftor. No new safety signals have been identified. The CHMP concluded that no changes to the product information are required based on the long-term |

<div style=\"page-break-after: always\"></div>

|                     | 11.5 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                        | results from study VX19-809-124.                                                                                                                                       |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0089           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 30/04/2024 |            | SmPC, Labelling and PL |                                                                                                                                                                        |
| PSUSA/10455 /202305 | Periodic Safety Update EU Single assessment - lumacaftor / ivacaftor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 25/01/2024 | 05/04/2024 | SmPC and PL            | Please refer to Orkambi EMEA/H/C/PSUSA/00010455/202305 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IG/1695/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 08/12/2023 | n/a        |                        |                                                                                                                                                                        |
| X/0078/G            | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 26/04/2023 | 04/07/2023 | SmPC, Labelling and    | Please refer to Scientific Discussion 'Orkambi                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         | Extension application to add a new strength of 75 mg of lumacaftor and 94 mg of ivacaftor fixed dose combination granules, grouped with a type II variation (C.I.6.a). Extension of indication to include treatment of cystic fibrosis for children aged 1 to less than 2 years old of age who are homozygous for the F508del mutation in the CFTR gene, based on final results from study 122, a 2-part study of CF subjects 1 to <2 years of age homozygous for F508del. As a consequence, sections 4.1, 4.2, 4.5, 4.6, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Annex II has also been updated. In addition, the MAH took the opportunity to implement minor updates in the Product Information. Version 11.4 of the RMP has also been approved. Annex I_2.(c) Change or addition of a new strength/potency C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            | PL       | EMEA/H/C/003954/X/0078/G\".                                                                                                                                                                                                                                                 |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0084 | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 29/05/2023 | n/a        |          |                                                                                                                                                                                                                                                                            |
| SW/0083 | Post Authorisation Safety Study results - EMEA/H/C/PSR/S/0039 - Variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 23/02/2023 | 26/04/2023 | Annex II | As the PASS is finalized, removal of the additional monitoring statement and the black triangle from the product information is warranted. Annex II of the product information is also updated to remove the PASS. Therefore, in view of available data regarding the PASS |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                        |            |            |                        | final study report, the PRAC considered that changes to the product information and to the conditions of the marketing authorisation were warranted.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0082           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                             | 09/03/2023 | 04/07/2023 | Annex II and PL        |                                                                                                                                                        |
| IA/0081             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                           | 05/12/2022 | n/a        |                        |                                                                                                                                                        |
| PSUSA/10455 /202205 | Periodic Safety Update EU Single assessment - lumacaftor / ivacaftor                                                                                                                   | 01/12/2022 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                      |
| IG/1530             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                       | 28/06/2022 | n/a        |                        |                                                                                                                                                        |
| IG/1460             | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                             | 13/12/2021 | 20/10/2022 | SmPC, Labelling and PL |                                                                                                                                                        |
| PSUSA/10455 /202105 | Periodic Safety Update EU Single assessment - lumacaftor / ivacaftor                                                                                                                   | 02/12/2021 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                      |
| IA/0075/G           | This was an application for a group of variations. A.z - Administrative change - Other variation B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s) | 15/10/2021 | 20/10/2022 | SmPC and PL            |                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| IA/0073             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                             | 03/08/2021   | n/a   |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IB/0069             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                | 03/06/2021   | n/a   |                                   |
| IAIN/0070           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                           | 20/04/2021   | n/a   |                                   |
| IB/0067             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                       | 14/04/2021   | n/a   |                                   |
| IA/0068             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 12/02/2021   | n/a   |                                   |
| PSUSA/10455 /202005 | Periodic Safety Update EU Single assessment - lumacaftor / ivacaftor                                                                                                                                                                         | 14/01/2021   | n/a   | PRAC Recommendation - maintenance |
| IG/1312/G           | This was an application for a group of variations. B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                | 04/12/2020   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|         | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0063 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                    | 25/11/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| R/0056  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                   | 17/09/2020 | 18/11/2020 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Orkambi in the approved indication remains favourable, but recommended that one additional five-year renewal be required based on the following pharmacovigilance grounds: The following pharmacovigilance issues require a second renewal of the marketing authorisation: • There is an ongoing PASS for Orkambi which aims to evaluate the long-term safety of lumacaftor/ivacaftor (LUM/IVA) therapy in patients with cystic fibrosis (CF). Given that this study is categorised as category 1 and the results are considered key to benefit risk it is considered appropriate to have a second renewal of the marketing authorisation. • There is limited exposure and post-marketing data available for the recent approvals in paediatric patients (6- 12 years and 2-5 years of age). |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                                  | • There is a planned PAES study to compare disease progression among children with CF homozygous for F508del-CFTR and aged 2 through 5 years at the time of Orkambi treatment initiation versus disease progression among concurrent matched cohort of children with CF who have never received Orkambi treatment, in addition to a longitudinal historical cohort. This study is expected to provide verification of the impact of Orkambi treatment on clinical outcomes (including long term safety) and disease progression and to confirm current efficacy and safety assumptions. Therefore, based upon the limited safety profile of Orkambi, the CHMP concluded that the MAH should submit one additional renewal application in 5 years' time.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0064  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 12/11/2020 | 20/10/2022 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| N/0061  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 21/09/2020 | 20/10/2022 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0055 | Update of section 4.8 of the SmPC with safety data in children from the Phase 3, open-label, multicentre rollover study for Study 115 Part B, designed to evaluate long-term safety of Orkambi treatment for 96 weeks in patients with cystic fibrosis, 2 years of age and older, homozygous for F508del. The MAH also took the opportunity to update the SmPC in line with the latest version of the QRD template v10.1. The Package Leaflet is updated accordingly. In addition, the RMP version 8.0 is acceptable. In addition, the RMP is updated and version 7,1 is | 09/07/2020 | 18/11/2020 | SmPC, Annex II, Labelling and PL | Long-term safety data from a 96-week rollover extension study in 57 patients aged 2 years and older who were homozygous for the F508del mutation in the CFTR gene were generally consistent with the 24-week parent study in patients aged 2 to 5 years (trial 8) and safety data in patients aged 6 to 11 years.                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0049   | Update of section 4.8 of the SmPC with the safety data and section 5.1 with the (secondary) efficacy data from the Phase 3, open-label, rollover study for Studies 109 and Study 011 Part B designed to evaluate the long-term safety and tolerability of Orkambi treatment for 96 weeks in patients with cystic fibrosis, 6 years of age and older, homozygous for F508del. The MAH also took the opportunity to include minor changes to section 4.5 of the Granules SmPC and sections 4.8 and 5.2 of the Tablets and Granules SmPC which were considered acceptable by CHMP. In addition, the RMP version 8.0 is acceptable. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 09/07/2020 | 18/11/2020 | SmPC | Patients with CF aged 6 years and older from trial 6 and trial 7 were included in a phase 3, multicentre, rollover extension study (trial 9). This extension trial was designed to evaluate the safety and efficacy of long-term treatment of lumacaftor/ivacaftor. Of the 262 patients who received any treatment in trial 6 or trial 7, 239 (91%) were dosed and received active treatment (patients 6 to <12 years of age received lumacaftor 200 mg q12h/ivacaftor 250 mg q12h; patients ≥12 years of age received lumacaftor 400 mg q12h/ivacaftor 250 mg q12h) in the extension study for up to an additional 96 weeks (i.e. up to a total of 120 weeks). Overall, long term safety data from a 96-week rollover extension study (Trial 9) in 239 patients aged 6 years and older who were homozygous for the F508del mutation in the CFTR gene were generally consistent with the 24-week parent studies in patients aged 6 to 11 years (Trial 6 and Trial 7). |
| IG/1180/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a                                                                                                                                                                                                                                                                                                                                                                                              | 17/06/2020 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | material/reagent/intermediate for AS - to quality control testing arrangements for AS -replacement or addition of a site where control/testing takes place                                                                                                                                                                                                                               |            |            |      | starting Changes the batch            |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------|
| IB/0059   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                | 29/05/2020 | 18/11/2020 | SmPC |                                       |
|           | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.g.5.b - Implementation of changes foreseen in an approved change management protocol - | 16/04/2020 | n/a        |      | IB/0057/G Requires further supporting |
| IB/0058   | B.II.g.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol                                                                                                                                                                                                                                                   | 08/04/2020 | n/a        |      |                                       |
| II/0053/G | This was an application for a group of variations. B.II.g.2 - Introduction of a post approval change management protocol related to the finished product B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                           | 16/01/2020 | n/a        |      |                                       |

<div style=\"page-break-after: always\"></div>

| PSUSA/10455 /201905   | Periodic Safety Update EU Single assessment - lumacaftor / ivacaftor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 28/11/2019   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| IA/0054               | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 14/11/2019   | n/a   |                                     |
| IA/0052/G             | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 20/09/2019   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

|                     | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                      |            |            |                 |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/10455 /201811 | Periodic Safety Update EU Single assessment - lumacaftor / ivacaftor                                                                                                                                                                                                                                                | 14/06/2019 | n/a        |                 | PRAC Recommendation - maintenance |
| IB/0048             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                       | 28/05/2019 | n/a        |                 |                                   |
| IB/0047             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                      | 10/05/2019 | n/a        |                 |                                   |
| IA/0045/G           | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                            | 04/03/2019 | n/a        |                 |                                   |
| IAIN/0046/G         | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing | 15/02/2019 | 11/02/2020 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IAIN/0044/G   | This was an application for a group of variations.                                       | 15/02/2019   | n/a   |           |
|---------------|------------------------------------------------------------------------------------------|--------------|-------|-----------|
| IB/0042       | B.II.d.2.d - Change in test procedure for the finished Other changes to a test procedure | 30/01/2019   | n/a   | product - |

<div style=\"page-break-after: always\"></div>

|           | (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| X/0034/G  | This was an application for a group of variations. The MAH applied for an addition of a new pharmaceutical form (granules) and an addition of two new strengths (100/125 mg and 150/188 mg) for paediatric use (2 to 5 years). In addition, the MAH updated sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.3, 6.3 and 6.4 of the SmPC of the tablets formulation to bring it in line with the safety updates proposed with the new paediatric granules formulation and its extension for use in 2-5 years old. Annex II, the PL and RMP v5.4 have been updated accordingly. Annex II, the PL and RMP v5.4 have been updated accordingly. Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 15/11/2018 | 15/01/2019 | SmPC, Labelling and PL |
| IA/0040/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 10/12/2018 | n/a        |                        |

<div style=\"page-break-after: always\"></div>

|                     | control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                   |            |            |                        |                                                                                                                                            |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10455 /201805 | Periodic Safety Update EU Single assessment - lumacaftor / ivacaftor                                                                                                                                                                                                                                                                                                                                                                                                     | 29/11/2018 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                          |
| IG/1018/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 28/11/2018 | n/a        |                        |                                                                                                                                            |
| T/0039              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                      | 26/10/2018 | 26/11/2018 | SmPC, Labelling and PL |                                                                                                                                            |
| IB/0036             | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                  | 15/10/2018 | n/a        |                        |                                                                                                                                            |
| PSUSA/10455 /201711 | Periodic Safety Update EU Single assessment - lumacaftor / ivacaftor                                                                                                                                                                                                                                                                                                                                                                                                     | 28/06/2018 | 23/08/2018 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10455/201711. |

<div style=\"page-break-after: always\"></div>

| IB/0035             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                        | 27/06/2018   | n/a        |                     |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| II/0030/G           | This was an application for a group of variations. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 22/03/2018   | n/a        |                     |                                                                                                                                            |
| PSUSA/10455 /201705 | Periodic Safety Update EU Single assessment - lumacaftor / ivacaftor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 14/12/2017   | 19/02/2018 | SmPC and PL         | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10455/201705. |
| WS/1284             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation                                                                                                                                                                                                                                                                                                                    | 15/02/2018   | n/a        |                     |                                                                                                                                            |
| IB/0032/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14/02/2018   | 23/08/2018 | SmPC, Labelling and |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.e - Stability of FP - Change to an approved stability protocol   |            |            | PL                               |                    |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------|
| IB/0031   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                       | 07/02/2018 | n/a        |                                  |                    |
| IG/0881   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                          | 11/01/2018 | n/a        |                                  |                    |
| X/0020    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                          | 09/11/2017 | 08/01/2018 | SmPC, Annex II, Labelling and PL |                    |
| II/0017   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                   | 14/12/2017 | 19/02/2018 | SmPC, Labelling and PL           |                    |
| IB/0025   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                          | 08/12/2017 | n/a        |                                  |                    |
| IB/0026/G | This was an application for a group of variations. B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test                        | 06/12/2017 | n/a        |                                  | B.I.b.1.d - Change |

<div style=\"page-break-after: always\"></div>

|                     | and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                       |            |            |             |                                                                                                                        |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------|
| WS/1187/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 14/09/2017 | n/a        |             |                                                                                                                        |
| II/0021             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                          | 14/09/2017 | 08/01/2018 | SmPC        |                                                                                                                        |
| PSUSA/10455 /201611 | Periodic Safety Update EU Single assessment - lumacaftor / ivacaftor                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22/06/2017 | 24/08/2017 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     | PSUSA/10455/201611.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------|
| IA/0023/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of | 16/08/2017 | n/a |                       |
| II/0018/G | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.g.1.a - Introduction of a new design space or extension of an approved design space for the                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 30/03/2017 | n/a |                       |

<div style=\"page-break-after: always\"></div>

|                     | finished product - One or more unit operations in the manuf. process of the FP including the resulting IPCs and/or test procedures                                                                                                                                                                                                                                                                                                                                                                      |            |            |      |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| WS/1047             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                             | 26/01/2017 | n/a        |      |                                   |
| IB/0015/G           | This was an application for a group of variations. B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits | 14/12/2016 | n/a        |      |                                   |
| II/0014             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                       | 08/12/2016 | 24/08/2017 | SmPC |                                   |
| PSUSA/10455 /201605 | Periodic Safety Update EU Single assessment - lumacaftor / ivacaftor                                                                                                                                                                                                                                                                                                                                                                                                                                    | 01/12/2016 | n/a        |      | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| II/0011/G   | This was an application for a group of variations. Grouping variation of 2 in-vitro studies to evaluate the potential off target activity of M6- ivacaftor to address post-authorisation measure MEA005. The MAH submitted a revised RMP to reflect information from these studies. In addition the MAH took the opportunity to update administrative aspects of the RMP. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission authority   | 15/09/2016   | n/a        |                   | of studies to the competent   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|-------------------------------|
| IG/0701     | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 04/08/2016   | n/a        |                   |                               |
| II/0005/G   | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered Annex which involve the submission                                                                                                                                                                                                        | 23/06/2016   | 23/12/2016 | SmPC and Annex II | elsewhere in this             |

<div style=\"page-break-after: always\"></div>

|           | studies to the competent authority - Other variations not specifically covered in this Annex which involve the submission studies to the competent authority                                                                                                                                                                                                                                                     |            |            |                        | of C.I.13 elsewhere of   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------|
| IB/0010   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                              | 10/06/2016 | 23/12/2016 | SmPC, Labelling and PL |                          |
| IA/0009/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                           | 20/05/2016 | n/a        |                        |                          |
| IB/0008/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.e.5.b - Implementation of changes foreseen in an approved change management protocol - Requires supportive data | 18/05/2016 | n/a        |                        | further                  |

<div style=\"page-break-after: always\"></div>

| II/0002   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                   | 28/04/2016   | 23/12/2016   | SmPC and PL            |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|
| IB/0004   | B.II.b.5.f - Change to in-process tests or limits applied during the manufacture of the finished product - Addition or replacement of an in-process test as a result of a safety or quality issue                                                                   | 23/03/2016   | n/a          |                        |
| IA/0006   | B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition                                                                                                                                                                   | 29/02/2016   | n/a          |                        |
| IB/0007/G | This was an application for a group of variations. B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 23/02/2016   | n/a          |                        |
| IB/0003   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                 | 07/01/2016   | 23/12/2016   | SmPC, Labelling and PL |